Jane Street Group LLC Sells 20,543 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Jane Street Group LLC decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 33.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,265 shares of the specialty pharmaceutical company's stock after selling 20,543 shares during the period. Jane Street Group LLC owned 0.13% of Collegium Pharmaceutical worth $1,182,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COLL. Freestone Grove Partners LP bought a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at about $319,000. AQR Capital Management LLC lifted its holdings in Collegium Pharmaceutical by 19.5% in the fourth quarter. AQR Capital Management LLC now owns 154,216 shares of the specialty pharmaceutical company's stock valued at $4,418,000 after buying an additional 25,206 shares during the period. Northern Trust Corp lifted its holdings in Collegium Pharmaceutical by 5.6% in the fourth quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock valued at $11,035,000 after buying an additional 20,490 shares during the period. Aquatic Capital Management LLC bought a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $461,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Collegium Pharmaceutical by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,138 shares of the specialty pharmaceutical company's stock worth $950,000 after acquiring an additional 1,977 shares during the period.

Insider Activity at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 1,949 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company's stock, valued at $5,315,850. The trade was a 1.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares of the company's stock, valued at $4,330,048.32. The trade was a 20.60% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Up 0.1%

Shares of NASDAQ COLL traded up $0.04 during mid-day trading on Monday, reaching $28.86. 178,265 shares of the company's stock were exchanged, compared to its average volume of 427,975. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a market capitalization of $927.33 million, a price-to-earnings ratio of 12.44 and a beta of 0.63. The business has a fifty day simple moving average of $28.09 and a 200 day simple moving average of $29.65.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business's quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter last year, the business posted $1.45 earnings per share. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on COLL. Needham & Company LLC reissued a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler reissued a "neutral" rating and set a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.